Search research articles
Contact Us
Filters
Showing results (41-50 of 83) with videos related to
Page
of 9
Sort By:
Lancet (London, England)
|
June 14, 2016
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold L Atkins, Marjorie Bowman, David Allan, et al.
Endocrine-Related Cancer
|
February 12, 2009
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours
Umasuthan Srirangalingam, Bernard Khoo, Lisa Walker, et al.
The Journal of Allergy and Clinical Immunology
|
August 2, 2016
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells
Hannah H Chen, Norman Händel, Joanne Ngeow, et al.
Breast Cancer Research : BCR
|
May 21, 2025
Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE
Nasim Mavaddat, Debra Frost, Emily Zhao, et al.
European Urology
|
June 14, 2020
Prostate Cancer Risk by BRCA2 Genomic Regions
Tommy Nyberg, Debra Frost, Daniel Barrowdale, et al.
Familial Cancer
|
January 17, 2017
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls
Sibel Saya, Emma Killick, Sarah Thomas, et al.
European Urology
|
September 10, 2019
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Tommy Nyberg, Debra Frost, Daniel Barrowdale, et al.
Journal of Medical Genetics
|
November 14, 2019
Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic <i>TP53</i> mutation carriers: a case-controlled study (SIGNIFY)
Elizabeth K Bancroft, Sibel Saya, Emma Brown, et al.
Journal of the National Cancer Institute
|
May 1, 2013
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE
Nasim Mavaddat, Susan Peock, Debra Frost, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
March 23, 2018
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study
Fabio Girardi, Daniel R Barnes, Daniel Barrowdale, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 83) with videos related to
Sort By:
Page
of 9
Lancet (London, England)
|
June 14, 2016
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold L Atkins, Marjorie Bowman, David Allan, et al.
Endocrine-Related Cancer
|
February 12, 2009
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours
Umasuthan Srirangalingam, Bernard Khoo, Lisa Walker, et al.
The Journal of Allergy and Clinical Immunology
|
August 2, 2016
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells
Hannah H Chen, Norman Händel, Joanne Ngeow, et al.
Breast Cancer Research : BCR
|
May 21, 2025
Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE
Nasim Mavaddat, Debra Frost, Emily Zhao, et al.
European Urology
|
June 14, 2020
Prostate Cancer Risk by BRCA2 Genomic Regions
Tommy Nyberg, Debra Frost, Daniel Barrowdale, et al.
Familial Cancer
|
January 17, 2017
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls
Sibel Saya, Emma Killick, Sarah Thomas, et al.
European Urology
|
September 10, 2019
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Tommy Nyberg, Debra Frost, Daniel Barrowdale, et al.
Journal of Medical Genetics
|
November 14, 2019
Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic <i>TP53</i> mutation carriers: a case-controlled study (SIGNIFY)
Elizabeth K Bancroft, Sibel Saya, Emma Brown, et al.
Journal of the National Cancer Institute
|
May 1, 2013
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE
Nasim Mavaddat, Susan Peock, Debra Frost, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
March 23, 2018
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study
Fabio Girardi, Daniel R Barnes, Daniel Barrowdale, et al.
Page
of 9